Autolus Therapeutics (NASDAQ:AUTL) Trading 3.3% Higher

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) rose 3.3% during mid-day trading on Thursday . The company traded as high as $5.40 and last traded at $5.32. Approximately 144,588 shares traded hands during trading, a decline of 91% from the average daily volume of 1,538,540 shares. The stock had previously closed at $5.15.

Analyst Ratings Changes

AUTL has been the topic of a number of recent research reports. Truist Financial increased their price objective on shares of Autolus Therapeutics from $10.00 to $11.00 and gave the company a "buy" rating in a research note on Tuesday. Needham & Company LLC reissued a "buy" rating and set a $9.00 target price on shares of Autolus Therapeutics in a research report on Thursday, March 14th. Finally, The Goldman Sachs Group increased their target price on shares of Autolus Therapeutics from $3.20 to $4.80 and gave the company a "neutral" rating in a research report on Wednesday, December 13th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $8.16.

Autolus Therapeutics Price Performance

The stock's 50-day moving average is $6.07 and its 200 day moving average is $4.99. The company has a market cap of $1.42 billion, a PE ratio of -4.50 and a beta of 1.90.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings results on Thursday, March 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.18). On average, analysts expect that Autolus Therapeutics plc will post -0.73 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Two Sigma Advisers LP purchased a new position in shares of Autolus Therapeutics in the first quarter worth $25,000. BNP Paribas Financial Markets increased its stake in shares of Autolus Therapeutics by 337.3% in the fourth quarter. BNP Paribas Financial Markets now owns 4,268 shares of the company's stock worth $27,000 after acquiring an additional 3,292 shares during the period. CI Private Wealth LLC acquired a new stake in shares of Autolus Therapeutics in the fourth quarter worth $28,000. Sei Investments Co. acquired a new stake in shares of Autolus Therapeutics in the fourth quarter worth $29,000. Finally, Advisor Group Holdings Inc. increased its stake in shares of Autolus Therapeutics by 3,285.0% in the fourth quarter. Advisor Group Holdings Inc. now owns 16,925 shares of the company's stock worth $32,000 after acquiring an additional 16,425 shares during the period. Hedge funds and other institutional investors own 72.83% of the company's stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.